Skip to main content

Advertisement

SpringerLink
Log in

BRAF Heterogeneity in Melanoma

  • Skin Cancer (T Ito, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

In the era of molecular targeted therapy, the accurate detection of BRAF mutation in melanoma has become increasingly important. With the advances of molecular analyses and immunohistochemistry, the presence of BRAF mutational heterogeneity in melanoma has been widely recognized. Although most patients with melanoma have a homogeneous BRAF mutation status because the BRAF mutation occurs at an early stage of melanoma development and acts as a driver gene mutation, BRAF mutational heterogeneity does exist, among different tumor sites of a single patient (intertumor heterogeneity) and/or even within a single tumor (intratumor heterogeneity). To summarize the published reports, about 10% of melanoma patients may show intertumorally discordant BRAF status and about 15% of BRAF-mutated melanomas may have intratumor BRAF heterogeneity, although the reported results vary strikingly among the studies and methods used. Considering the BRAF heterogeneity of melanoma, a single biopsy from a single tumor may not be sufficient to uncover the entire BRAF status of a patient. Multiple samples from different sites may be preferable to assess the indication of BRAF/MEK inhibitors, as recommended by the current clinical guidelines. The impact of BRAF heterogeneity on patient survival or the response to treatment with BRAF/MEK inhibitors is an interesting issue, but requires further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.

    Google Scholar 

  2. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714–36.

    PubMed  PubMed Central  Google Scholar 

  3. Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, et al. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst Rev. 2019;7(7):CD012806. https://doi.org/10.1002/14651858.CD012806.pub2.

    Article  PubMed  Google Scholar 

  4. Bastian BC, de la Fouchardiere A, Elder DE, Gerami P, Lazar AJ, Massi D, et al. WHO classification of skin tumors. 4th ed: IARC; 2018.

  5. Bradish JR, Cheng L. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. Hum Pathol. 2014;45(7):1315–26.

    CAS  PubMed  Google Scholar 

  6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.

    CAS  PubMed  Google Scholar 

  7. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One. 2012;7:e29336.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer. 2011;104(3):464–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Verlinden I, van den Hurk K, Clarijs R, Willig AP, Stallinga CM, Roemen GM, et al. BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article. Medicine (Baltimore). 2014;93(28):e285.

    CAS  Google Scholar 

  12. • Grzywa TM, Paskal W, Włodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956–75 A comprehensive review on intratumor and intertumor heterogeneity of melanoma, including BRAF and other genes.

  13. Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry. Oncotarget. 2017;8(5):8069–82.

    PubMed  Google Scholar 

  14. Fisher KE, Cohen C, Siddiqui MT, Palma JF, Lipford EH 3rd, Longshore JW. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol. 2014;45(11):2281–93.

    CAS  PubMed  Google Scholar 

  15. Lamy PJ, Castan F, Lozano N, Montélion C, Audran P, Bibeau F, et al. Next-generation genotyping by digital PCR to detect and quantify the BRAF V600E mutation in melanoma biopsies. J Mol Diagn. 2015;17(4):366–73.

    CAS  PubMed  Google Scholar 

  16. Chang GA, Wiggins JM, Corless BC, Syeda MM, Tadepalli JS, Blake S, et al. TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors. J Invest Dermatol. 2020;140(8):1609–18.e7.

    CAS  PubMed  Google Scholar 

  17. Ito T, Kaku-Ito Y, Murata M, Furue K, Shen CH, Oda Y, et al. Immunohistochemical BRAF V600E expression and intratumor BRAF V600E heterogeneity in acral melanoma: implication in melanoma-specific survival. J Clin Med. 2020;9(3):690.

    CAS  PubMed Central  Google Scholar 

  18. Ito T, Kaku-Ito Y, Murata M, Ichiki T, Kuma Y, Tanaka Y, et al. Intra- and inter-tumor BRAF heterogeneity in acral melanoma: an immunohistochemical analysis. Int J Mol Sci. 2019;20(24):6191. https://doi.org/10.3390/ijms20246191.

    Article  CAS  PubMed Central  Google Scholar 

  19. NCCN Guidelines Version 4. 2020 Cutaneous Melanoma. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed 27 Sep 2020.

  20. Thiel A, Moza M, Kytölä S, Orpana A, Jahkola T, Hernberg M, et al. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. Hum Pathol. 2015;46(2):169–75.

    CAS  PubMed  Google Scholar 

  21. • Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis. Eur J Cancer. 2017;81:106–15 A meta-analysis showing intertumor heterogeneity between primary–metastatic and metastatic–metastatic melanoma lesions.

    CAS  PubMed  Google Scholar 

  22. Nakamura Y, Asai J, Igaki H, Inozume T, Namikawa K, Hayashi A, et al. Japanese dermatological association guidelines: outlines of guidelines for cutaneous melanoma 2019. J Dermatol. 2020;47(2):89–103.

    PubMed  Google Scholar 

  23. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment-update 2019. Eur J Cancer. 2020;126:159–77.

    CAS  PubMed  Google Scholar 

  24. Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–50.

    Google Scholar 

  25. Pellegrini C, Cardelli L, Padova M, Nardo LD, Ciciarelli V, Rocco T, et al. Intra-patient heterogeneity of BRAF and NRAS molecular alterations in primary melanoma and metastases. Acta Derm Venereol. 2020;100(1):adv00040.

    CAS  PubMed  Google Scholar 

  26. • Kaji T, Yamasaki O, Takata M, Otsuka M, Hamada T, Morizane S, et al. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: a clue for intra- and inter-tumor heterogeneity. J Dermatol Sci. 2017;85(1):51–7 A comparative study on driver mutations in melanoma showing intratumor and intertumor heterogeneity.

  27. Yaman B, Kandiloğlu G, Akalin T. BRAF-V600 mutation heterogeneity in primary and metastatic melanoma: a study with pyrosequencing and immunohistochemistry. Am J Dermatopathol. 2016;38(2):113–20.

    PubMed  Google Scholar 

  28. Manfredi L, Meyer N, Tournier E, Grand D, Uro-Coste E, Rochaix P, et al. Highly concordant results between immunohistochemistry and molecular testing of mutated V600E BRAF in primary and metastatic melanoma. Acta Derm Venereol. 2016;96(5):630–4.

    CAS  PubMed  Google Scholar 

  29. Casula M, Colombino M, Manca A, Caracò C, Botti G, Ascierto PA, et al. Low levels of genetic heterogeneity in matched lymph node metastases from patients with melanoma. J Invest Dermatol. 2016;136(9):1917–20.

    CAS  PubMed  Google Scholar 

  30. Bradish JR, Richey JD, Post KM, Meehan K, Sen JD, Malek AJ, et al. Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Mod Pathol. 2015;28(4):480–6.

    CAS  PubMed  Google Scholar 

  31. Nardin C, Puzenat E, Prétet JL, Algros MP, Doussot A, Puyraveau M, et al. BRAF mutation screening in melanoma: is sentinel lymph node reliable? Melanoma Res. 2015;25(4):328–34.

    CAS  PubMed  Google Scholar 

  32. Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, et al. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget. 2015;6(35):37895–905.

    PubMed  PubMed Central  Google Scholar 

  33. Eriksson H, Zebary A, Vassilaki I, Omholt K, Ghaderi M, Hansson J. BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases. JAMA Dermatol. 2015;151(4):410–6.

    PubMed  Google Scholar 

  34. Riveiro-Falkenbach E, Villanueva CA, Garrido MC, Ruano Y, García-Martín RM, Godoy E, et al. Intra- and inter-tumoral homogeneity of BRAF(V600E) mutations in melanoma tumors. J Invest Dermatol. 2015;135(12):3078–85.

    CAS  PubMed  Google Scholar 

  35. Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol. 2014;38(3):377–82.

    PubMed  Google Scholar 

  36. Saint-Jean M, Quéreux G, Nguyen JM, Peuvrel L, Brocard A, Vallée A, et al. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol. 2014;134(5):1468–70.

    CAS  PubMed  Google Scholar 

  37. Saroufim M, Habib RH, Gerges R, Saab J, Loya A, Amr SS, et al. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. Exp Mol Pathol. 2014;97(3):315–20.

    CAS  PubMed  Google Scholar 

  38. Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Törngren T, et al. Molecular and genetic diversity in the metastatic process of melanoma. J Pathol. 2014;233(1):39–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Boursault L, Haddad V, Vergier B, Cappellen D, Verdon S, Bellocq JP, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One. 2013;8(8):e70826.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Heinzerling L, Baiter M, Kühnapfel S, Schuler G, Keikavoussi P, Agaimy A, et al. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer. 2013;109(11):2833–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med. 2013;11:202.

    PubMed  PubMed Central  Google Scholar 

  42. Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci. 2013;72(3):284–9.

    CAS  PubMed  Google Scholar 

  43. Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol. 2013;169(5):1049–55.

    CAS  PubMed  Google Scholar 

  44. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522–9.

    PubMed  Google Scholar 

  45. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10(5):1753–7.

    CAS  PubMed  Google Scholar 

  46. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:6.

    PubMed  PubMed Central  Google Scholar 

  47. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483–8.

    CAS  PubMed  Google Scholar 

  48. Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer. 2015;15:497.

    PubMed  PubMed Central  Google Scholar 

  49. Fernandes M, Barcelos D, Comodo AN, Guimarães DP, Lopes Carapeto FC, Cardili L, et al. Acral lentiginous melanomas harbour intratumor heterogeneity in BRAF exon 15, with mutations distinct from V600E/V600K. Am J Dermatopathol. 2019;41(10):733–40.

    PubMed  Google Scholar 

  50. Sakaizawa K, Ashida A, Kiniwa Y, Okuyama R. BRAF mutation heterogeneity in melanoma lesions. Acta Derm Venereol. 2020;100(1):adv00045.

    PubMed  Google Scholar 

  51. Betancourt LH, Szasz AM, Kuras M, Rodriguez Murillo J, Sugihara Y, Pla I, et al. The hidden story of heterogeneous B-raf V600E mutation quantitative protein expression in metastatic melanoma-association with clinical outcome and tumor phenotypes. Cancers (Basel). 2019;11(12):1981.

    CAS  Google Scholar 

  52. Cintra Lopes Carapeto F, Neves Comodo A, Germano A, Pereira Guimarães D, Barcelos D, Fernandes M, et al. Marker protein expression combined with expression heterogeneity is a powerful indicator of malignancy in acral lentiginous melanomas. Am J Dermatopathol. 2017;39(2):114–20.

    PubMed  Google Scholar 

  53. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer. 2012;106(5):939–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2013;37(3):413–20.

    PubMed  Google Scholar 

  55. Ito T, Kaku-Ito Y, Wada-Ohno M, Furue M. Narrow-margin excision for invasive acral melanoma: is it acceptable? J Clin Med. 2020;9(7):2266.

    PubMed Central  Google Scholar 

  56. Wada M, Ito T, Tsuji G, Nakahara T, Hagihara A, Furue M, et al. Acral lentiginous melanoma versus other melanoma: a single-center analysis in Japan. J Dermatol. 2017;44(8):932–8.

    CAS  PubMed  Google Scholar 

  57. Ito T, Wada M, Nagae K, Nakano-Nakamura M, Nakahara T, Hagihara A, et al. Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? J Am Acad Dermatol. 2015;72(1):71–7.

    PubMed  Google Scholar 

  58. Fusi A, Berdel R, Havemann S, Nonnenmacher A, Keilholz U. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Eur J Cancer. 2011;47(13):1971–6.

    CAS  PubMed  Google Scholar 

  59. Mesbah Ardakani N, Leslie C, Grieu-Iacopetta F, Lam WS, Budgeon C, Millward M, et al. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma. Pigment Cell Melanoma Res. 2017;30(2):233–42.

    CAS  PubMed  Google Scholar 

  60. Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, et al. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer. 2013;108(4):924–31.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka, 812-8582, Japan

    Takamichi Ito MD, PhD, Yuka Tanaka PhD, Maho Murata MD, Yumiko Kaku-Ito MD, Kazuhisa Furue MD & Masutaka Furue MD, PhD

Authors
  1. Takamichi Ito MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuka Tanaka PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maho Murata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yumiko Kaku-Ito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhisa Furue MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masutaka Furue MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takamichi Ito MD, PhD.

Ethics declarations

Conflict of interest

Takamichi Ito declares that he has no conflict of interest. Yuka Tanaka declares that he has no conflict of interest. Maho Murata declares that he has no conflict of interest. Yumiko Kaku-Ito declares that he has no conflict of interest. Kazuhisa Furue declares that he has no conflict of interest. Masutaka Furue declares that he has no conflict of interest.

Human and animal rights and informed consent

This article does not describe any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ito, T., Tanaka, Y., Murata, M. et al. BRAF Heterogeneity in Melanoma. Curr. Treat. Options in Oncol. 22, 20 (2021). https://doi.org/10.1007/s11864-021-00818-3

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00818-3

Keywords

Search

Navigation